- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Development and Use of Diagnostic Testing
Bryan Loy, MD, discusses how the FDA approval process for emerging diagnostic tests is becoming more rigorous and well defined. He notes that this guidance should be of help in theplanning stages of test development. Dr Loy explains that many of these tests are being developed in the laboratory industry rather than the pharmaceutical industry. He insists that innovation should not be stifled, and that it is in everyone’s interest to move tests quickly through the approval process to market while ensuring their validity.
Dr Loy is uncertain about how well providers really understand the development process, or in some cases, even the quality, the analytic validity, and the methodology of those tests. Therefore, adoption will be based on a variety of factors including price point, accessibility, decentralization, interpretability of the information, ease of doing business, and ability to return results fast enough to avoid delaying therapy.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
